Managing patient flows in radiation oncology during the COVID-19 pandemic : Reworking existing treatment designs to prevent infections at a German hot spot area University Hospital.
Appointments and Schedules
COVID-19
/ diagnosis
COVID-19 Testing
/ statistics & numerical data
Cross Infection
/ epidemiology
Dose Fractionation, Radiation
Germany
/ epidemiology
Hospitals, University
/ organization & administration
Humans
Infection Control
/ methods
Infectious Disease Transmission, Patient-to-Professional
/ prevention & control
Infectious Disease Transmission, Professional-to-Patient
/ prevention & control
Neoplasms
/ radiotherapy
Outpatient Clinics, Hospital
/ organization & administration
Pandemics
Personal Protective Equipment
Procedures and Techniques Utilization
Radiation Oncology
/ organization & administration
Radiology Department, Hospital
/ organization & administration
Radiosurgery
/ statistics & numerical data
Radiotherapy
/ statistics & numerical data
SARS-CoV-2
/ isolation & purification
Triage
/ methods
Workflow
COVID-19, SARS-CoV-2
Disease transmission, infectious
Radiation dose hypofractionation
Radiation oncology
Stereotactic radiosurgery
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
31
05
2020
accepted:
26
09
2020
pubmed:
31
10
2020
medline:
15
12
2020
entrez:
30
10
2020
Statut:
ppublish
Résumé
The described work aimed to avoid cancellations of indispensable treatments by implementing active patient flow management practices and optimizing infrastructure utilization in the radiation oncology department of a large university hospital and regional COVID-19 treatment center close to the first German SARS-CoV‑2 hotspot region Heinsberg in order to prevent nosocomial infections in patients and personnel during the pandemic. The study comprised year-to-date intervention analyses of in- and outpatient key procedures, machine occupancy, and no-show rates in calendar weeks 12 to 19 of 2019 and 2020 to evaluate effects of active patient flow management while monitoring nosocomial COVID-19 infections. Active patient flow management helped to maintain first-visit appointment compliance above 85.5%. A slight appointment reduction of 10.3% daily (p = 0.004) could still significantly increase downstream planning CT scheduling (p = 0.00001) and performance (p = 0.0001), resulting in an absolute 20.1% (p = 0.009) increment of CT performance while avoiding overbooking practices. Daily treatment start was significantly increased by an absolute value of 18.5% (p = 0.026). Hypofractionation and acceleration were significantly increased (p = 0.0043). Integrating strict testing guidelines, a distancing regimen for staff and patients, hygiene regulations, and precise appointment scheduling, no SARS-CoV‑2 infection in 164 tested radiation oncology service inpatients was observed. In times of reduced medical infrastructure capacities and resources, controlling infrastructural time per patient as well as optimizing facility utilization and personnel workload during treatment evaluation, planning, and irradiation can help to improve appointment compliance and quality management. Avoiding recurrent and preventable exposure to healthcare infrastructure has potential health benefits and might avert cross infections during the pandemic. Active patient flow management in high-risk COVID-19 regions can help Radiation Oncologists to continue and initiate treatments safely, instead of cancelling and deferring indicated therapies.
Identifiants
pubmed: 33123776
doi: 10.1007/s00066-020-01698-6
pii: 10.1007/s00066-020-01698-6
pmc: PMC7595566
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1080-1085Commentaires et corrections
Type : ErratumIn
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Appl Clin Inform. 2014 Sep 24;5(3):836-60
pubmed: 25298821
Nat Rev Clin Oncol. 2020 May;17(5):268-270
pubmed: 32242095
Subst Use Misuse. 2013 Jun;48(9):743-9
pubmed: 23607670
Blood. 2020 May 21;135(21):1829-1832
pubmed: 32275740
J Prim Care Community Health. 2013 Oct;4(4):251-5
pubmed: 24327664
China CDC Wkly. 2020 Feb 21;2(8):113-122
pubmed: 34594836
JAMA. 2020 Apr 28;323(16):1610-1612
pubmed: 32129805
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Lancet Glob Health. 2020 Apr;8(4):e488-e496
pubmed: 32119825
Am J Med. 2010 Jun;123(6):542-8
pubmed: 20569761
Nature. 2020 Jun;582(7813):557-560
pubmed: 32340022
Int J Health Care Qual Assur. 2016 May 9;29(4):475-88
pubmed: 27142954
J Health Care Finance. 2006 Spring;32(3):39-52
pubmed: 18975731
Radiother Oncol. 2020 Jun;147:227-228
pubmed: 32342862
Strahlenther Onkol. 2020 May;196(5):417-420
pubmed: 32211940